1,724 Shares in Aetna Inc (AET) Acquired by Girard Partners LTD.

Girard Partners LTD. purchased a new stake in shares of Aetna Inc (NYSE:AET) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,724 shares of the company’s stock, valued at approximately $316,000.

Other large investors have also bought and sold shares of the company. Cornerstone Advisors Inc. increased its position in Aetna by 263.6% in the 1st quarter. Cornerstone Advisors Inc. now owns 600 shares of the company’s stock worth $101,000 after purchasing an additional 435 shares during the last quarter. Bruderman Asset Management LLC acquired a new position in Aetna in the 1st quarter worth about $118,000. Centaurus Financial Inc. acquired a new position in Aetna in the 1st quarter worth about $128,000. Kaizen Advisory LLC increased its position in Aetna by 143.9% in the 2nd quarter. Kaizen Advisory LLC now owns 766 shares of the company’s stock worth $141,000 after purchasing an additional 452 shares during the last quarter. Finally, Clearwater Capital Advisors LLC acquired a new position in Aetna in the 1st quarter worth about $154,000. 84.98% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have weighed in on the company. ValuEngine raised Aetna from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. Zacks Investment Research raised Aetna from a “sell” rating to a “hold” rating in a research report on Monday, August 6th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $202.00 target price on shares of Aetna in a research report on Thursday, August 2nd. Finally, Credit Suisse Group dropped their target price on Aetna from $208.00 to $194.00 and set a “neutral” rating on the stock in a research report on Monday, May 14th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $200.38.



AET opened at $196.95 on Wednesday. The stock has a market cap of $63.69 billion, a PE ratio of 19.97, a P/E/G ratio of 1.67 and a beta of 0.67. Aetna Inc has a 52-week low of $149.69 and a 52-week high of $197.63. The company has a quick ratio of 0.74, a current ratio of 0.74 and a debt-to-equity ratio of 0.44.

Aetna (NYSE:AET) last released its quarterly earnings results on Thursday, August 2nd. The company reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.04 by $0.39. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $15.59 billion. Aetna had a return on equity of 20.66% and a net margin of 5.77%. The firm’s revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.42 EPS. equities research analysts forecast that Aetna Inc will post 11.27 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 1st. Stockholders of record on Wednesday, July 25th were paid a dividend of $0.50 per share. The ex-dividend date was Tuesday, July 24th. This represents a $2.00 annualized dividend and a dividend yield of 1.02%. Aetna’s dividend payout ratio (DPR) is presently 20.28%.

Aetna Company Profile

Aetna Inc operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis.

Further Reading: How are Outstanding Shares Different from Authorized Shares?

Institutional Ownership by Quarter for Aetna (NYSE:AET)

Receive News & Ratings for Aetna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply